Literature DB >> 2195027

Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.

D P Williams1, C E Snider, T B Strom, J R Murphy.   

Abstract

We have used cassette and deletion mutagenesis to analyze the structural features of fragment B-related sequences in the fusion toxin DAB486-IL-2 (where IL-2 represents interleukin-2) that are necessary for the efficient delivery of fragment A to the cytosol of target cells. We demonstrate that whereas an intact disulfide bond between Cys461 and Cys471 may be required for the cytotoxic action of native diphtheria toxin, this bond is not required for the cytotoxic action of DAB486-IL-2. The in-frame deletion of the 97 amino acids from Thr387 to His485 of DAB486-IL-2 increases both the potency and the apparent dissociation constant (Kd) of the resulting fusion toxin for high affinity interleukin-2 receptor-bearing target cells. In contrast, the inframe deletion of either the 191 amino acids between Asp291 and Gly483 or the 85 amino acids between Asn204 and Ile290 results in a 1000-fold loss in potency. These regions contain the putative membrane-spanning regions and the amphipathic membrane surface-associating regions of fragment B, respectively. These results indicate that the efficient delivery of the ADP-ribosyltransferase from DAB486-IL-2 to the cytosol requires the membrane-associating domains of fragment B. This function has been postulated to play a role in the diphtherial intoxication of eukaryotic cells. However, unlike native diphtheria toxin, fragment B sequences distal to Thr387 do not enhance the potency of DAB486-IL-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195027

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

Authors:  V K Chaudhary; M G Gallo; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

3.  Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

Authors:  Laurene S Cheung; Juan Fu; Pankaj Kumar; Amit Kumar; Michael E Urbanowski; Elizabeth A Ihms; Sadiya Parveen; C Korin Bullen; Garrett J Patrick; Robert Harrison; John R Murphy; Drew M Pardoll; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

4.  Essential lysine residues within transmembrane helix 1 of diphtheria toxin facilitate COPI binding and catalytic domain entry.

Authors:  Carolina Trujillo; Julian Taylor-Parker; Robert Harrison; John R Murphy
Journal:  Mol Microbiol       Date:  2010-04-14       Impact factor: 3.501

5.  Expression of ricin B chain in Spodoptera frugiperda.

Authors:  A Frankel; H Roberts; H Gulick; L Afrin; J Vesely; M Willingham
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

6.  Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.

Authors:  Seunguk Oh; John R Ohlfest; Deborah A Todhunter; Vincent D Vallera; Walter A Hall; Hua Chen; Daniel A Vallera
Journal:  J Neurooncol       Date:  2009-06-11       Impact factor: 4.130

7.  Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.

Authors:  J vanderSpek; L Cosenza; T Woodworth; J C Nichols; J R Murphy
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

8.  Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.

Authors:  Mark Fogg; John R Murphy; Jochen Lorch; Marshall Posner; Fred Wang
Journal:  Virology       Date:  2013-04-17       Impact factor: 3.616

9.  Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor.

Authors:  J G Pickering; P A Bacha; L Weir; J Jekanowski; J C Nichols; J M Isner
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  David Kaminetzky; Kenneth B Hymes
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.